Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers (Tables)

v3.22.2
Revenues from Contracts and Significant Customers (Tables)
6 Months Ended
Jun. 30, 2022
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

Three months ended June 30, 

Six Months Ended June 30, 

    

2022

    

2021

    

2022

    

2021

Revenue

Qbrexza®

$

6,111

$

4,568

$

13,487

4,568

Accutane®

5,200

1,945

10,107

2,141

Amzeeq®

1,265

4,731

Targadox®

2,756

5,727

5,390

$

12,926

Ximino®

1,035

1,312

2,002

3,413

Zilxi®

555

1,297

Exelderm®

1,313

1,736

2,017

2,953

Other branded revenue

6

Collaboration revenue

577

2,400

1,154

3,200

Revenue – related party

 

18

 

155

 

70

 

223

Other revenue

56

2,556

 

Net revenue

$

18,886

$

17,843

$

42,811

$

29,430